Calithera Biosciences

Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients.

Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors.

In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

Company Growth (employees)
South San Francisco, US
Size (employees)
44 (est)+26%
Calithera Biosciences was founded in 2010 and is headquartered in South San Francisco, US

Calithera Biosciences Office Locations

Calithera Biosciences has an office in South San Francisco
South San Francisco, US (HQ)
200 343 Oyster Point Blvd

Calithera Biosciences Data and Metrics

Calithera Biosciences Financial Metrics

Numbers are in $, USD

Net income (FY, 2016)

(38 m)

EBIT (FY, 2016)

(38.3 m)

Market capitalization (24-May-2017)

584.1 m

Closing share price (24-May-2017)


Cash (31-Dec-2016)

10.6 m
Calithera Biosciences's current market capitalization is $584.1 m.
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

R&D expense

16.4 m23.7 m27.7 m

General and administrative expense

5.4 m9.1 m10.6 m

Operating expense total

21.7 m32.8 m38.3 m


(21.7 m)(32.8 m)(38.3 m)

Interest income

9 k175 k330 k

Net Income

(21.7 m)(32.6 m)(38 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016


102 m6.1 m10.6 m


1.9 m2.6 m1.8 m

Current Assets

103.9 m72.5 m53.6 m


861 k931 k899 k

Total Assets

104.8 m75.8 m54.8 m

Accounts Payable

693 k562 k398 k

Current Liabilities

4.1 m3.8 m4.5 m

Additional Paid-in Capital

152.2 m156.4 m172.4 m

Retained Earnings

(51.9 m)(84.5 m)(122.5 m)

Total Equity

100.4 m71.8 m49.9 m

Financial Leverage

1 x1.1 x1.1 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(21.7 m)(32.6 m)(38 m)

Depreciation and Amortization

361 k404 k297 k


(1.5 m)(673 k)787 k

Accounts Payable

543 k(131 k)(28 k)

Cash From Operating Activities

(19.2 m)(29.9 m)(31 m)

Purchases of PP&E

(556 k)(441 k)(401 k)

Cash From Investing Activities

(486 k)(66.8 m)23.7 m

Cash From Financing Activities

87.9 m845 k11.8 m
Y, 2016

Financial Leverage

1.1 x

Calithera Biosciences Operating Metrics

FY, 2016

Phase 1/2


Phase I Trials


Calithera Biosciences Market Value History

Calithera Biosciences Online and Social Media Presence

Calithera Biosciences Company Life and Culture

You may also be interested in